ClinConnect ClinConnect Logo
Search / Trial NCT06872346

Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT

Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 6, 2025

Trial Information

Current as of April 26, 2025

Not yet recruiting

Keywords

Cervical Cancer Screening Clinical Decision Support

ClinConnect Summary

This clinical trial, called PREDICT, is looking at a personalized way to follow up on cervical cancer screening. The goal is to see if different methods of reminding patients about their screenings can improve their care. Participants will be women aged 21 to 70 who have been screened for cervical cancer in the past few years and are considered at higher risk for developing serious conditions. The trial will divide participants into three groups: one will receive standard care, another will get reminders based on their visits, and the third will have reminders plus outreach programs to help them stay on track with their screenings.

To be eligible for this trial, women need to have a cervix, be within the specified age range, and have received care at a participating clinic recently. They must have had a Pap test or HPV test in the last 3.5 years and have results indicating a higher risk for cervical issues. Those who have been treated for cervical cancer, have had their cervix removed, or are not fluent in English or Spanish cannot participate. While the study is not yet recruiting participants, those who join can expect to receive personalized follow-up based on their health needs, which may help improve their overall cervical health.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria, Individuals who:
  • have a cervix and are 21-70 years old
  • receive care at a participating primary care practice (i.e. PCP team visit within past 3 years)
  • have had a Pap and/ or HPV test within the past 3.5 years
  • has a CCSM result that suggest a 5-year risk of developing CIN3+ that warrants surveillance at 1 or 3 years, diagnostic colposcopy, or treatment (i.e., above average risk).
  • Inclusion of those up to age 70 is intended to identify individuals whose prior history does not meet screening exit criteria, and warrants surveillance or diagnostic care even though women with adequate prior screening can stop at age 65
  • Exclusion Criteria Individuals who:
  • were diagnosed with cervical cancer/ CIN3+ prior to the most recent screening Pap or HPV test
  • have had their cervix removed
  • are not English or Spanish-speaking.

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported